Eye lens implant safety study pulled before starting
NCT ID NCT06541795
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study was designed to check the long-term safety and performance of AcrySof IQ Vivity lens implants in people who had them in both eyes for 3 to 5 years. It was a real-world observation, not a treatment test. However, the study was withdrawn before enrolling any participants, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AcrySof IQ Vivity Extended Vision intraocular lens (IOL) and AcrySof IQ Vivity Toric Extended Vision IOL
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for APHAKIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Contact Alcon Call Center for Trial Locations
Fort Worth, Texas, 76134, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Laser eye surgery may offer a One-Time fix for reading glasses — a trial puts it to the test
- Eye drops may offer a new way to read without glasses — a trial puts them to the test
- Tiny corneal lens holds up after 4 years for near vision
- Could a micro implant replace reading glasses?
- New contact lens swap could mean better comfort for aging eyes
- Which reading glasses give the best view? new study puts three lens designs to the test